EPIZYME INC (EPZM) Stock Price, Quote, News and Overview
NASDAQ:EPZM - Nasdaq - US29428V1044 - Common Stock - Currency: USD
EPZM Quote, Performance and Key Statistics
1.47
-0.02 (-1.34%)
The current stock price of EPZM is 1.47 USD. In the past month the price decreased by -0.68%. In the past year, price decreased by -72.78%.
EPZM Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About EPZM
Company Profile
Epizyme, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 250 full-time employees. The company went IPO on 2013-05-31. The firm is engaged in the treatment of people with cancer through the discovery, development, and commercialization of epigenetic medicines. The firm's lead product TAZVERIK (tazemetostat) is used for epithelioid sarcoma (ES), and follicular lymphoma (FL). Tazemetostat is an oral, selective small molecule inhibitor of the EZH2 histone methyltransferase (HMT), for the treatment of adult and pediatric patients aged 16 years and older with metastatic or locally advanced ES not eligible for complete resection. The company is developing tazemetostat for lymphomas and B-cell malignancies, including B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), multiple myeloma and others. Its advanced product candidate, EZM0414, is an oral inhibitor of the SETD2 HMT. The firm is assessing the use of tazemetostat for immuno-oncology-sensitive tumors, such as small cell lung cancer, prostate cancer, and others.
Company Info
EPIZYME INC
400 Technology Sq Ste 4
Cambridge MASSACHUSETTS 02139 US
CEO: Robert B. Bazemore
Employees: 250
Company Website: http://www.epizyme.com/
Phone: 16172295872.0
EPIZYME INC / EPZM FAQ
What is the stock price of EPIZYME INC today?
The current stock price of EPZM is 1.47 USD. The price decreased by -1.34% in the last trading session.
What is the ticker symbol for EPIZYME INC stock?
The exchange symbol of EPIZYME INC is EPZM and it is listed on the Nasdaq exchange.
On which exchange is EPZM stock listed?
EPZM stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for EPIZYME INC stock?
9 analysts have analysed EPZM and the average price target is 3.04 USD. This implies a price increase of 107% is expected in the next year compared to the current price of 1.47. Check the EPIZYME INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is EPIZYME INC worth?
EPIZYME INC (EPZM) has a market capitalization of 247.44M USD. This makes EPZM a Micro Cap stock.
How many employees does EPIZYME INC have?
EPIZYME INC (EPZM) currently has 250 employees.
What are the support and resistance levels for EPIZYME INC (EPZM) stock?
EPIZYME INC (EPZM) has a support level at 1.46 and a resistance level at 1.47. Check the full technical report for a detailed analysis of EPZM support and resistance levels.
Is EPIZYME INC (EPZM) expected to grow?
The Revenue of EPIZYME INC (EPZM) is expected to grow by 28.63% in the next year. Check the estimates tab for more information on the EPZM EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy EPIZYME INC (EPZM) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of EPZM, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of EPZM, evaluating the profitability, health, valuation and growth aspects
- EPIZYME INC (EPZM) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- EPIZYME INC (EPZM) Sales and EPS estimates to see what analysts future expectations are.
- EPIZYME INC (EPZM) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- EPIZYME INC (EPZM) Insider and Institutional Ownership to learn about the owners and their transactions.
- EPIZYME INC (EPZM) Stock Chart to make your own analysis
- EPIZYME INC (EPZM) Latest news and press-releases to stay up to date.
Does EPIZYME INC (EPZM) stock pay dividends?
EPZM does not pay a dividend.
When does EPIZYME INC (EPZM) report earnings?
EPIZYME INC (EPZM) will report earnings on 2022-11-07.
What is the Price/Earnings (PE) ratio of EPIZYME INC (EPZM)?
EPIZYME INC (EPZM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.68).
EPZM Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to EPZM. When comparing the yearly performance of all stocks, EPZM is one of the better performing stocks in the market, outperforming 97.75% of all stocks.
EPZM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to EPZM. Both the profitability and financial health of EPZM have multiple concerns.
EPZM Financial Highlights
Over the last trailing twelve months EPZM reported a non-GAAP Earnings per Share(EPS) of -1.68. The EPS increased by 33.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -391.89% | ||
| ROA | -78.64% | ||
| ROE | N/A | ||
| Debt/Equity | -11.48 |
EPZM Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to EPZM. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 43.15% and a revenue growth 28.63% for EPZM